Latest Breaking News On - Betta pharmaceuticals co - Page 1 : comparemela.com

Merus MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting | 03 06 24

Merus MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting | 03 06 24
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesChicago mayAmerican society of clinical oncologyExchange commissionBetta pharmaceuticals coAnnual meetingBill lundbergChief executive officerHepatocyte growth factor receptorBetta pharmaceuticalsPrivate securities litigation reform actAnnual report

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
finanzen.ch - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.ch Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomBristol myers squibbEli lillyAsia pacificMeru biclonicsZenocutuzumab zenoIllinois state universityCompany newsWashington university in stIncyte corporationDrug administrationGilead sciencesExchange commissionBetta pharmaceuticals coCompany lilly

Merus N V : Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

Merus N V : Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomZenocutuzumab zenoMeru biclonicsBristol myers squibbEli lillyAsia pacificIllinois state universityArray biopharma incIncyte corporationCompany lillyWashington university in stInvitae corporationGilead sciencesCompany newsExchange commission

Comparing Merus (NASDAQ:MRUS) & Travere Therapeutics (NASDAQ:TVTX)

Comparing Merus (NASDAQ:MRUS) & Travere Therapeutics (NASDAQ:TVTX)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoRetrophin incTravere therapeutics incIncyte corporationAlagille syndrome allianceTranslational sciencesNational institutes of health centerBetta pharmaceuticals coTravere therapeuticsGet free reportGiven travere therapeuticIga nephropathyOrphan drug designationNational institutesNational center

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

- Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial - Petosemtamab in 2L+ HNSCC phase 3 trial planned to initiate mid-2024; interim clinical data planned for 2H24 - Petosemtamab in 2L CRC: cohort planned to initiate in 2024 - Zeno in NRG1+ cancer: Sufficient clinical data expected in 1H24 to support potential BLA submissions - Based on the Company’s current operating plan, existing cash, cash equival

United statesUnited kingdomMeru biclonicsEli lillyZenocutuzumab zenoAmerican association of cancer researchExchange commissionUs food drug administrationBetta pharmaceuticals coEuropean society for medical oncologyIncyte corporationEarly access programSasia congressCompany lillyCorporate communicationsBill lundberg